The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
机构:[1]Guangzhou Univ Chinese Med, Clin Med Sch 2, Guangzhou, Peoples R China广东省中医院[2]Guangdong Prov Hosp Tradit Chinese Med, Emergency Dept, Guangzhou, Peoples R China大德路总院急诊科大德路总院急诊科广东省中医院[3]Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Peoples R China[4]Hubei Univ Arts & Sci, Dept Nursing, Xiangyang, Peoples R China[5]Guangdong Prov Key Lab Res Emergency Tradit Chines, Clin Res Team Prevent & Treatment Cardiac Emergenc, Guangzhou, Peoples R China[6]Shenzhen Tradit Chinese Med Hosp, Shenzhen, Peoples R China
Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. Methods: PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical , China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. Results: A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). Conclusion: OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results.Systematic Review Registration: URL = , CRD 42022316534
基金:
National Natural Science Foundation of China; Municipal School (college) Joint Funding Project of Guangzhou Municipal Science and Technology Foundation; Science and Technology Foundation of Shenzhen City; Guangdong Medical Research Foundation; [81273961]; [81303117]; [202201020352]; [JCYJ20190812164009243]; [B2020135]
第一作者机构:[1]Guangzhou Univ Chinese Med, Clin Med Sch 2, Guangzhou, Peoples R China
通讯作者:
通讯机构:[1]Guangzhou Univ Chinese Med, Clin Med Sch 2, Guangzhou, Peoples R China[2]Guangdong Prov Hosp Tradit Chinese Med, Emergency Dept, Guangzhou, Peoples R China[5]Guangdong Prov Key Lab Res Emergency Tradit Chines, Clin Res Team Prevent & Treatment Cardiac Emergenc, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Huang Peiying,Li Zhishang,Chen Li,et al.The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials[J].FRONTIERS IN PHARMACOLOGY.2022,13:doi:10.3389/fphar.2022.918689.
APA:
Huang, Peiying,Li, Zhishang,Chen, Li,Zeng, Jing,Zhao, Shuai...&Chen, Bojun.(2022).The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials.FRONTIERS IN PHARMACOLOGY,13,
MLA:
Huang, Peiying,et al."The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials".FRONTIERS IN PHARMACOLOGY 13.(2022)